Specific biomarker predicts which HER2-negative breast cancer patients respond to tar
 

A multicenter team led by Case Western Reserve has demonstrated that brief exposure to a targeted therapy can tell doctors which HER2-negative patients will respond — and which should switch to another kind of treatment.

More...